Australia markets close in 1 hour 32 minutes

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.74-0.02 (-0.19%)
At close: 04:00PM EST
10.75 +0.01 (+0.09%)
After hours: 07:46PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 810.09M
Enterprise value 506.50M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.20
Price/book (mrq)4.61
Enterprise value/revenue 3.26
Enterprise value/EBITDA -20.26

Trading information

Stock price history

Beta (5Y monthly) 3.62
52-week change 3-57.42%
S&P500 52-week change 324.55%
52-week high 329.90
52-week low 35.41
50-day moving average 37.24
200-day moving average 314.48

Share statistics

Avg vol (3-month) 31.89M
Avg vol (10-day) 32.24M
Shares outstanding 591.85M
Implied shares outstanding 6N/A
Float 868.95M
% held by insiders 19.04%
% held by institutions 187.70%
Shares short (14 Nov 2021) 48.89M
Short ratio (14 Nov 2021) 45.33
Short % of float (14 Nov 2021) 417.09%
Short % of shares outstanding (14 Nov 2021) 49.67%
Shares short (prior month 14 Oct 2021) 48.15M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin -21.79%
Operating margin (ttm)-21.23%

Management effectiveness

Return on assets (ttm)-5.47%
Return on equity (ttm)-18.60%

Income statement

Revenue (ttm)155.27M
Revenue per share (ttm)1.70
Quarterly revenue growth (yoy)8,843.20%
Gross profit (ttm)-57.35M
EBITDA -27.05M
Net income avi to common (ttm)-33.83M
Diluted EPS (ttm)-0.37
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)347.39M
Total cash per share (mrq)3.78
Total debt (mrq)43.79M
Total debt/equity (mrq)24.92
Current ratio (mrq)3.79
Book value per share (mrq)1.91

Cash flow statement

Operating cash flow (ttm)40.62M
Levered free cash flow (ttm)29.95M